Goldman Sachs Reinstates Buy on Insmed, Announces $188 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 78.7%

Neg 0% Neu 78.7% Pos 0%

Goldman Sachs analyst Andrea Newkirk reinstates Insmed (NASDAQ:INSM) with a Buy and announces $188 price target.

Comments

No comments yet. Be the first!